- Home
- GNLX vs LXEO Comparison
GNLX vs LXEO Comparison
Compare GNLX & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- LXEO
- Stock Information
- Founded
- GNLX 2001
- LXEO 2017
- Country
- GNLX United States
- LXEO United States
- Employees
- GNLX N/A
- LXEO N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- LXEO
- Sector
- GNLX Health Care
- LXEO
- Exchange
- GNLX Nasdaq
- LXEO Nasdaq
- Market Cap
- GNLX 129.9M
- LXEO 93.9M
- IPO Year
- GNLX 2023
- LXEO 2023
- Fundamental
- Price
- GNLX $3.53
- LXEO $4.65
- Analyst Decision
- GNLX Strong Buy
- LXEO Strong Buy
- Analyst Count
- GNLX 5
- LXEO 5
- Target Price
- GNLX $16.20
- LXEO $16.60
- AVG Volume (30 Days)
- GNLX 153.8K
- LXEO 435.8K
- Earning Date
- GNLX 08-13-2025
- LXEO 08-11-2025
- Dividend Yield
- GNLX N/A
- LXEO N/A
- EPS Growth
- GNLX N/A
- LXEO N/A
- EPS
- GNLX N/A
- LXEO N/A
- Revenue
- GNLX N/A
- LXEO N/A
- Revenue This Year
- GNLX N/A
- LXEO N/A
- Revenue Next Year
- GNLX N/A
- LXEO N/A
- P/E Ratio
- GNLX N/A
- LXEO N/A
- Revenue Growth
- GNLX N/A
- LXEO N/A
- 52 Week Low
- GNLX $1.60
- LXEO $1.45
- 52 Week High
- GNLX $5.89
- LXEO $13.63
- Technical
- Relative Strength Index (RSI)
- GNLX 58.36
- LXEO 61.04
- Support Level
- GNLX $3.30
- LXEO $3.60
- Resistance Level
- GNLX $3.60
- LXEO $4.31
- Average True Range (ATR)
- GNLX 0.26
- LXEO 0.33
- MACD
- GNLX 0.00
- LXEO -0.00
- Stochastic Oscillator
- GNLX 75.71
- LXEO 71.95
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.